Shorla Oncology Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
46
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$18M
- Investors
-
5
Shorla Oncology General Information
Description
Developer of oncology medicines designed to improve existing cancer treatments through reformulated and alternative presentations. The company develops products for rare and orphan cancers, including pediatric and ovarian indications, addressing gaps in availability and administration of established oncology drugs, enabling healthcare institutions to access treatments that resolve limitations with traditional formulations.
Contact Information
Website
www.shorlaoncology.comCorporate Office
- Questum Acceleration Center
- Ballingarrane Science & Technology Park, County Tipperary
- Clonmel E91 V329
- Ireland
Corporate Office
- Questum Acceleration Center
- Ballingarrane Science & Technology Park, County Tipperary
- Clonmel E91 V329
- Ireland
Shorla Oncology Timeline
Shorla Oncology Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC | 17-Jan-2026 | $18M | Completed | Generating Revenue | ||
| 5. Later Stage VC (Series B) | 04-Oct-2023 | Completed | Generating Revenue | |||
| 4. Early Stage VC (Series A) | 01-Jun-2022 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series A) | 16-Feb-2021 | Completed | Generating Revenue | |||
| 2. Grant | 01-Jan-2019 | $114K | $2.21M | Completed | Generating Revenue | |
| 1. Angel (individual) | $2.21M | $2.21M | Completed | Startup |
Shorla Oncology Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series B | ||||||||
| Series B | ||||||||
| Series A | ||||||||
| Ordinary | 1,000,000 | $0.001065 | $1.07 | $1.07 | 1x | $1.07 | 3.19% | |
| Ordinary | 1,000,000 | $0.001065 | $0.85 | $0.85 | 1x | $0.85 | 3.19% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Shorla Oncology Comparisons
Industry
Financing
Details
Shorla Oncology Competitors (99)
One of Shorla Oncology’s 99 competitors is Pfizer (Vienna), a Corporation company based in Vienna, Austria.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Pfizer (Vienna) | Corporation | Vienna, Austria | ||||
| Genentech | Formerly VC-backed | South San Francisco, CA | ||||
| Aprea Therapeutics | Formerly VC-backed | Doylestown, PA | ||||
| Bridge Medicines | Venture Capital-Backed | New York, NY | ||||
| Teon Therapeutics | Venture Capital-Backed | Redwood City, CA |
Shorla Oncology Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Shorla Oncology Patents
Shorla Oncology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024290762-A1 | Oral compositions comprising temozolomide or lenalidomide | Pending | 06-Jul-2023 | ||
| EP-4739289-A1 | Oral compositions comprising temozolomide or lenalidomide | Pending | 06-Jul-2023 | ||
| WO-2025008797-A1 | Oral compositions comprising temozolomide or lenalidomide | Inactive | 06-Jul-2023 | ||
| US-20250017918-A1 | Oral suspensions comprising temozolomide or lenalidomide | Pending | 06-Jul-2023 | ||
| AU-2023220025-A1 | Stable formulations comprising thiotepa | Pending | 16-Feb-2022 | A61K9/0019 |
Shorla Oncology Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Shorla Oncology Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Kurma Partners | Venture Capital | Minority | ||
| Enterprise Ireland | Growth/Expansion | Minority | ||
| Kellysan Enterprises | PE/Buyout | Minority | ||
| Seroba Life Sciences | Venture Capital | Minority | ||
| Local Enterprise | Government |
Shorla Oncology Investments (1)
Shorla Oncology’s most recent deal was a Corporate Asset Purchase with Therakind (Jylamvo Drug). The deal was made on 31-Oct-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Therakind (Jylamvo Drug) | 31-Oct-2023 | Corporate Asset Purchase | Buildings and Property |
Shorla Oncology FAQs
-
When was Shorla Oncology founded?
Shorla Oncology was founded in 2018.
-
Where is Shorla Oncology headquartered?
Shorla Oncology is headquartered in Clonmel, Ireland.
-
What is the size of Shorla Oncology?
Shorla Oncology has 46 total employees.
-
What industry is Shorla Oncology in?
Shorla Oncology’s primary industry is Pharmaceuticals.
-
Is Shorla Oncology a private or public company?
Shorla Oncology is a Private company.
-
What is Shorla Oncology’s current revenue?
The current revenue for Shorla Oncology is .
-
How much funding has Shorla Oncology raised over time?
Shorla Oncology has raised $65.9M.
-
Who are Shorla Oncology’s investors?
Kurma Partners, Enterprise Ireland, Kellysan Enterprises, Seroba Life Sciences, and Local Enterprise have invested in Shorla Oncology.
-
Who are Shorla Oncology’s competitors?
Pfizer (Vienna), Genentech, Aprea Therapeutics, Bridge Medicines, and Teon Therapeutics are some of the 99 competitors of Shorla Oncology.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
